CYP3A5 genotype impacts Maraviroc concentrations in healthy volunteers

Drug Metabolism and Disposition

Volumn 42, Issue 11, 2014, Pages 1796-1802

  Lu, Yanhui ^a   Fuchs, Edward J ^b   Hendrix, Craig W ^a,b   Bumpus, Namandjé N ^a  

^a Division of Clinical Pharmacology   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; MARAVIROC; CYCLOHEXANE DERIVATIVE; CYTOCHROME P450 3A; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PRIMER DNA; TRIAZOLE DERIVATIVE;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENOTYPE; HEALTH STATUS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; METABOLITE; NORMAL HUMAN; SINGLE DRUG DOSE; ADOLESCENT; BLOOD; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BASE SEQUENCE; CYCLOHEXANES; CYTOCHROME P-450 CYP3A; DNA PRIMERS; HEALTHY VOLUNTEERS; HETEROZYGOTE; HIV FUSION INHIBITORS; HOMOZYGOTE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; TRIAZOLES; YOUNG ADULT;

EID: 84907465087     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.060194     Document Type: Article

References (54)

1. Abel S, Back DJ, and Vourvahis M (2009a) Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 14:607-618.
2. Abel S, Davis JD, Ridgway CE, Hamlin JC, and Vourvahis M (2009b) Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. Antivir Ther 14:831-837.
3. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, and Muirhead GJ (2008a) Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 65 (Suppl 1):38-46.
4. Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, and Muirhead GJ (2008b) Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 65 (Suppl 1):27-37.
5. Abel S, Russell D, Whitlock LA, Ridgway CE, and Muirhead GJ (2008c) Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/ levonorgestrel in healthy volunteers. Br J Clin Pharmacol 65 (Suppl 1):19-26.
6. Abel S, Russell D, Whitlock LA, Ridgway CE, and Muirhead GJ (2008d) The effects of cotrimoxazole or tenofovir co-Administration on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 65 (Suppl 1):47-53.
7. Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, and Walker DK (2008e) Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 65 (Suppl 1):60-67.
8. Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, and Muirhead GJ (2008f) Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 65 (Suppl 1): 5-18.
9. Andrews E, Glue P, Fang J, Crownover P, Tressler R, and Damle B (2010) Assessment of the pharmacokinetics of co-Administered maraviroc and raltegravir. Br J Clin Pharmacol 69: 51-57.
10. Asberg A, Midtvedt K, van Guilder M, Storset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, and Neely MN (2013) Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int 26:1198-1207.
11. Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, Spacek MB, Heidt PE, Cohen MS, and Kashuba AD (2011) Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis 203: 1484-1490.
12. Chan PL, Weatherley B, and McFadyen L (2008) A population pharmacokinetic meta-Analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol 65 (Suppl 1):76-85.
13. Chou FC, Tzeng SJ, and Huang JD (2001) Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 29:1205-1209.
14. Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13-31.
15. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, and Napier C, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49:4721-4732.
16. Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, Tressler R, Worsley J, and Kashuba AD (2009) Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 51:546-553.
17. Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RH, and van Schaik RH (2013) CYP3A4 intron 6 C.T SNP (CYP3A4 22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 14:137-149.
18. Emory JF, Seserko LA, and Marzinke MA (2014) Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma. Clin Chim Acta 431:198-205.
19. FDA (2007) Selzentry (Maraviroc): Clinical Pharmacology and Biopharmaceutics Review(s), US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD.
20. FDA 2013 Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, Rockville, MD.
21. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL, Jr, Bhat K, Kim RB, and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European-And African-American men and women. Pharmacogenetics 13:595-606.
22. Fung KL and Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794:860-871.
23. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, and Backman JT (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98:79-85.
24. Gruber VA, Rainey PM, Lum PJ, Beatty GW, Aweeka FT, and McCance-Katz EF (2013) Interactions between alcohol and the HIV entry inhibitor Maraviroc. J Int Assoc Provid AIDS Care 12:375-377.
25. Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S, and Heera JR (2014) Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr 65:78-81.
26. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, and Wohlfeiler M, et al.; MOTIVATE Study Teams (2008) Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359:1429-1441.
27. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, and Eichelbaum M, et al. (2000) Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
28. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, and Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
29. Hyland R, Dickins M, Collins C, Jones H, and Jones B (2008) Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 66:498-507.
30. Jacqmin P, Wade JR, Weatherley B, Snoeck E, Marshall S, and McFadyen L (2013) Assessment of maraviroc exposure-response relationship at 48 weeks in treatment-experienced HIV-1-infected patients in the MOTIVATE studies. CPT Pharmacometrics Syst Pharmacol 2:e64.
31. Kakuda TN, Abel S, Davis J, Hamlin J, Schöller-Gyüre M, Mack R, Ndongo N, Petit W, Ridgway C, and Sekar V, et al. (2011) Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. Antimicrob Agents Chemother 55:2290-2296.
32. Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, and Kroemer HK (1996) Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 42:387-389.
33. Kolars JC, Lown KS, Schmiedlin-Ren P, GhoshM, Fang C,Wrighton SA, Merion RM, andWatkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
34. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, and Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
35. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
36. Lee SJ and Goldstein JA (2005) Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6:357-371.
37. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
38. Lu Y, Hendrix CW, and Bumpus NN (2012) Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc. Drug Metab Dispos 40:2221-2230.
39. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, and Sheppard HW (1997) The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 3:338-340.
40. Moore RD (2011) Epidemiology of HIV infection in the United States: implications for linkage to care. Clin Infect Dis 52 (Suppl 2):S208-S213.
41. Mora-Peris B, Croucher A, Else LJ, Vera JH, Khoo S, Scullard G, Back D, and Winston A (2013) Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. J Antimicrob Chemother 68:1348-1353.
42. Okoli C, Siccardi M, Thomas-William S, Dufty N, Khonyongwa K, Ainsworth J, Watson J, Cook R, Gandhi K, and Hickinbottom G, et al. (2012) Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J Antimicrob Chemother 67: 671-674.
43. Philpott SM (2003) HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 1:217-227.
44. Pozniak AL, Boffito M, Russell D, Ridgway CE, and Muirhead GJ (2008) A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Br J Clin Pharmacol 65 (Suppl 1):54-59.
45. Ramanathan S, Abel S, Tweedy S, West S, Hui J, and Kearney BP (2010) Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. J Acquir Immune Defic Syndr 53: 209-214.
46. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, and Schwab M (2001) Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358: 383-384.
47. Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan WS, Castagna A, and Lazzarin A, et al. (2010) Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T.C polymorphism. Pharmacogenet Genomics 20:759-765.
48. Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, and Eron JJ, et al. (2013) Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr 64:167-173.
49. Tseng E, Walsky RL, Luzietti RA, Jr, Harris JJ, Kosa RE, Goosen TC, Zientek MA, and Obach RS (2014) Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). Drug Metab Dispos 42:1163-1173.
50. van Schaik RH, van der Heiden IP, van den Anker JN, and Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671.
51. Vourvahis M, Plotka A, Mendes da Costa L, Fang A, and Heera J (2013) Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects. Antimicrob Agents Chemother 57:6158-6164.
52. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, and Smith DA (2005) Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 33:587-595.
53. Wang D, Guo Y, Wrighton SA, Cooke GE, and Sadee W (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11: 274-286.
54. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.